SyntheMed REPEL-CV Receives Russian Approval
SyntheMed announced that its REPEL-CV barrier has received approval from the Ministry of Health of the Russian Federation for use in all patients who undergo open heart surgery.
richard l. franklin
SyntheMed Receives Endorsement, New Patent
REPEL-CV, a bioresorbable anti-adhesion barrier developed by biomaterials company SyntheMed, has received an endorsement from Kids with Heart.
SyntheMed Nominated for Frost & Sullivan Award
The Iselin, NJ-based company was recognized for its REPEL-CV Anti-Adhesion Barrier.